Harbour BioMed and Bristol Myers Squibb signed a discovery and development collaboration centered on next‑generation multi‑specific antibody therapeutics. Harbour will receive $90 million upfront and up to $1.035 billion in development and commercial milestones, plus tiered royalties if programs advance. The deal leverages Harbour’s Harbour Mice human‑antibody platform and BMS’s global development capabilities; Harbour highlighted opportunities to accelerate early clinical work by conducting trials in China. Management emphasized the strategic and financial importance of platform partnerships to catalyze antibody pipelines.